Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitorsJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92025-01-011PRE
Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug DesignACS MEDICINAL CHEMISTRY LETTERSIF42024-11-061OAAI
Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome InhibitorsJOURNAL OF MEDICINAL CHEMISTRYIF6.82023-07-289OAAI
Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase MetabolismJOURNAL OF MEDICINAL CHEMISTRYIF6.82021-12-208PRE
Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding ModeJOURNAL OF MEDICINAL CHEMISTRYIF6.82021-09-113PRE
Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δACS MEDICINAL CHEMISTRY LETTERSIF42020-06-036OAAI
Targeting the Regulatory Site of ER Aminopeptidase 1 Leads to the Discovery of a Natural Product Modulator of Antigen PresentationJOURNAL OF MEDICINAL CHEMISTRYIF6.82020-02-2830PREAI
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target口服可生物利用的PI3Kδ 抑制剂的优化和Vps34作为关键选择性靶标的鉴定JOURNAL OF MEDICINAL CHEMISTRYIF6.82019-12-1919PREAI
Mechanism for antigenic peptide selection by endoplasmic reticulum aminopeptidase 1PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.12019-12-1640OAAI
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.12019-04-08115OAAI
High-Resolution Crystal Structure of Endoplasmic Reticulum Aminopeptidase 1 with Bound Phosphinic Transition-State Analogue InhibitorACS MEDICINAL CHEMISTRY LETTERSIF42019-02-1331OAAI
Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase δ through a Deconstruction and Regrowth ApproachJOURNAL OF MEDICINAL CHEMISTRYIF6.82018-12-1110PREAI
Isoxazolopyrimidine-Based Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial ActivityACS OMEGAIF4.32018-08-1525OAAI
Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenaseNATURE COMMUNICATIONSIF15.72017-06-1243OAAI
Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute PancreatitisJOURNAL OF MEDICINAL CHEMISTRYIF6.82017-04-1125OAAI
Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease (vol 59, pg 7239, 2016)JOURNAL OF MEDICINAL CHEMISTRYIF6.82016-10-110PREAI
Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease (vol 59, pg 7239, 2016)JOURNAL OF MEDICINAL CHEMISTRYIF6.82016-08-221OAAI
Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory DiseaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82016-07-2728OAAI
Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitisNATURE MEDICINEIF502016-01-11132OAAI
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory DiseaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82015-09-03127PREAI